Levodopa Dose Equivalency in Parkinson's Disease: Updated Systematic Review and ProposalsStefanie T. Jost, Marie‐Ann Kaldenbach, Angelo Antonini et al.|Movement Disorders|2023Cited by 351
Plasma fibronectin is a prognostic biomarker of disability in Parkinson’s disease: a prospective, multicenter cohort studyShuzhen Zhu, Qing Wang, Shujuan Yang et al.|npj Parkinson s Disease|2025Cited by 18
A Holistic Wellness Prescription for Parkinson's Disease: Evidence‐Based Perspectives and Unmet NeedsIndu Subramanian, Lucia Ricciardi, Anette Schrag et al.|Movement Disorders Clinical Practice|2025Cited by 4
A 5-Year Longitudinal, Multicentre Validation Study Assessing the Prognostic Value of Plasma Fibronectin in a Cohort of Parkinson's Disease ParticipantsShuzhen Zhu, Hualin Li, Zifeng Huang et al.|SSRN Electronic Journal|2023Cited by 0
Plasma Fibronectin is a Prognostic Biomarker of Disability in Parkinson's Disease: A Prospective, Multicenter Cohort StudyShuzhen Zhu, Hualin Li, Zifeng Huang et al.|SSRN Electronic Journal|2024Cited by 0